Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning

被引:84
作者
Cohen, J
Gandhi, M
Naik, P
Cubitt, D
Rao, K
Thaker, U
Davis, EG
Gaspar, HB
Amrolia, PJ
Veys, P
机构
[1] Great Ormond St Hosp Sick Children, Dept Bone Marrow Transplant, London WC1N 3JH, England
[2] Great Ormond St Hosp Sick Children, Dept Bone Marrow Transplant, London WC1N 3JH, England
[3] Great Ormond St Hosp Sick Children, Dept Virol, London WC1N 3JH, England
[4] Great Ormond St Hosp Sick Children, Dept Clin Immunol, London WC1N 3JH, England
关键词
Epstein-Barr virus; lymphoproliferative disease; reduced-intensity conditioning; stem cell transplant; viraemia;
D O I
10.1111/j.1365-2141.2005.05439.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incidence of Epstein-Barr virus (EBV) viraemia and lymphoproliferative disease (LPD) was studied in a consecutive cohort of 128 paediatric patients undergoing stem cell transplantation (SCT) with reduced-intensity conditioning (RIC; n = 65) or conventional-intensity conditioning (CIC; n = 68). Following CIC, six of 68 (8%) developed viraemia; all remained asymptomatic. EBV viraemia (23 of 65 patients = 35%, P < 0.001) and LPD (10 of 65 = 15%, P < 0.001) were significantly more frequent following RIC. Of the 23 RIC patients who developed viraemia, eight remained asymptomatic, five had symptomatic viraemia (fever rash), and 10 patients developed LPD, two of whom died. An absolute lymphocyte count of < 03 x 10(9)/l at the time of onset of viraemia was strongly predictive of development of LPD (P < 0.05) in this group. The incidence of viraemia was significantly higher in patients receiving serotherapy with antithymocyte globulin (ATG; 15 of 43, 35%) than Campath (12 of 73, 16-4%, P < 0.05). Primary immunodeficiency and acute graft-versus-host disease were associated with EBV viraemia in univariate analysis, but were not independent risk factors. In conclusion, EBV viraemia and LPD appear to be significantly more common in children following RIC SCT, particularly with selective depletion of recipient T cells relative to B cells following the use of ATG. This probably reflects the profound immunosuppression following RIC SCT, together with the incomplete ablation of recipient-derived B cells.
引用
收藏
页码:229 / 239
页数:11
相关论文
共 32 条
[1]   Nonmyeloablative stem cell transplantation for congenital immunodeficiencies [J].
Amrolia, P ;
Gaspar, HB ;
Hassan, A ;
Webb, D ;
Jones, A ;
Sturt, N ;
Mieli-Vergani, G ;
Pagliuca, A ;
Mufti, G ;
Hadzic, N ;
Davies, G ;
Veys, P .
BLOOD, 2000, 96 (04) :1239-1246
[2]  
ANTIN JH, 1991, BLOOD, V78, P2139
[3]   Malignant neoplasms following bone marrow transplantation [J].
Bhatia, S ;
Ramsay, NKC ;
Steinbuch, M ;
Dusenbery, KE ;
Shapiro, RS ;
Weisdorf, DJ ;
Robison, LL ;
Miller, JS ;
Neglia, JP .
BLOOD, 1996, 87 (09) :3633-3639
[4]   Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation [J].
Chakrabarti, S ;
Milligan, DW ;
Pillay, D ;
Mackinnon, S ;
Holder, K ;
Kaur, N ;
McDonald, D ;
Fegan, CD ;
Waldmann, H ;
Hale, G ;
Rickinson, A ;
Steven, N .
BLOOD, 2003, 102 (03) :839-842
[5]   High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution [J].
Chakrabarti, S ;
Mackinnon, S ;
Chopra, R ;
Kottaridis, PD ;
Peggs, K ;
O'Gorman, P ;
Chakraverty, R ;
Marshall, T ;
Osman, H ;
Mahendra, P ;
Craddock, C ;
Waldmann, H ;
Hale, G ;
Fegan, CD ;
Yong, K ;
Goldstone, AH ;
Linch, DC ;
Milligan, DW .
BLOOD, 2002, 99 (12) :4357-4363
[6]  
Curtis RE, 1999, BLOOD, V94, P2208
[7]   Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children [J].
Faye, A ;
Quartier, P ;
Reguerre, Y ;
Lutz, P ;
Carret, AS ;
Dehée, A ;
Rohrlich, P ;
Peuchmaur, M ;
Matthieu-Boué, A ;
Fischer, A ;
Vilmer, E .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :112-118
[8]   B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome [J].
Gross, TG ;
Steinbuch, M ;
DeFor, T ;
Shapiro, RS ;
McGlave, P ;
Ramsay, NKC ;
Wagner, JE ;
Filipovich, AH .
BONE MARROW TRANSPLANTATION, 1999, 23 (03) :251-258
[9]   Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants [J].
Hale, G ;
Wardman, H .
BLOOD, 1998, 91 (08) :3079-3083
[10]   World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997 [J].
Harris, NL ;
Jaffe, ES ;
Diebold, J ;
Flandrin, G ;
Muller-Hermelink, HK ;
Vardiman, J ;
Lister, TA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3835-3849